Glenmark to end FY21 with better margins led by low expenses, India sales growth and US business rebound
The company said the worst is behind in terms of US business and expects an uptick in sales from Q3FY21 onwards.09-11-2020
09-11-2020
Earnings Call for Q2FY21 of Glenmark Pharmaceuticals Ltd.
Conference Call with Glenmark Pharmaceuticals Ltd. Management and Analysts on Q2FY21 Performance and Outlook. Listen to the full earnings transcript.09-11-2020
Glenmark Q2 net profit at Rs 234 crore
The company's consolidated revenue stood at Rs 2,952.47 crore for the quarter under consideration. It was Rs 2,815.04 crore for the same period a year ago, it added.06-11-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended September 30, 2020
Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2020. The said meeting of the Board commenced at 5.00 p.m. and concluded at 8.45 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com.06-11-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Notice of the Board Meeting published in newspapers viz. the Free Press Journal and Navshakti on October 28, 2020.28-10-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Cessation
Pursuant to Regulation 30 read with Schedule III Part A Para A (7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have to inform you that Mr. Milind Sarwate (DIN: 00109854) was appointed as Non Executive Independent Director of the Company for a term of Five Years commencing from October 29, 2015 to October 28, 2020. Mr. Milind Sarwate, has conveyed that due to his pre-occupation, he would be unable to continue as Director on the Board of the Company post completion of his term as Non-Executive Independent Director with effect from close of business hours on October 28, 2020. Hence, Mr. Milind Sarwate ceases to be a Director of the Company from close of business hours on October 28, 2020.28-10-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Monday, November 9, 2020 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.28-10-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, November 6, 2020, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2020. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2020 to November 8, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2020.27-10-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Intimation for The Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2020
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2020 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2020. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2020 to November 8, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2020.27-10-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Shareholding for the Period Ended September 30, 2020
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here19-10-2020